Join
Live feed
·
PRReleasevia Quantisnow
Exscientia Plc logo

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

ByQuantisnow·Wall Street's wire, on your screen.
EXAI· Exscientia Plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EXAI (Exscientia Plc) and more on Quantisnow.